Explore more by category

Filter

Period

Filter by

recent search

Showing: 15 of 216 stories

Driving Progress in Rare Liver Disease: Ipsen at EASL Congress 2026
 • 0 mins read

 – 0 mins read

Driving Progress in Rare Liver Disease: Ipsen at EASL Congress 2026

We’re excited to be at the European Association for the Study of the Liver (EASL) Congress 2026, Europe’s largest event dedicated to liver health where doctors, scientists, allied health professionals, patients, and industry partners come together to share knowledge, highlight scientific breakthroughs, and build meaningful connections.


A moment worth remembering: what SCALE tells us about the future of aesthetics 
 • 2 mins read

 – 2 mins read

A moment worth remembering: what SCALE tells us about the future of aesthetics 

There are moments that stay with you. Not because of a single slide or headline, but because you can feel something changing. Expectations shift. Standards rise. A new chapter begins. 


Driven by patients, delivering on our strategy: 2025 Integrated Annual Report now available
 • 1 mins read

 – 1 mins read

Driven by patients, delivering on our strategy: 2025 Integrated Annual Report now available

Ipsen’s 2025 Integrated Annual report report is now available on Ipsen.com. This essential reference document brings together key information and insights into the major developments in 2025 and what lies ahead.


Right medicine, right person: Jacintha Sivarajah on science with purpose
 • 1 mins read

 – 1 mins read

Right medicine, right person: Jacintha Sivarajah on science with purpose

“All medicines have side effects, but it’s just about trying to minimize the impact through providing the information patients and clinicians need or finding other ways to mitigate that impact.” — Jacintha Sivarajah 


Aesthetics, built from science
 • 2 mins read

 – 2 mins read

Aesthetics, built from science

Ipsen is not new to aesthetics. For more than three decades, we have been advancing neuroscience innovations across therapeutic and aesthetic indications, building deep expertise in complex biologics, rigorous clinical development and high‑quality manufacturing.